mains the leading cause of death in the United States. In 1988,511,080 Americans died of coronary heart disease (NCHS, 1989) . The morbidity from the disease disables even more. Yet a 44% decline in CHD mortality has occurred since 1972 (NCHS, 1989) . This national decline in CHD death has been affected, in part, by the efforts Americans have devoted to reducing their risks for the disease.
Particular gains have been made in identifying and controlling, or eliminating, major modifiable risk factors for CHD-high blood cholesterol and cigarette smoking. For example, fewer adults smoke today than did a decade ago. Today, an estimated 33% of men and 28% of women smoke-a 42% decline among men and a 28% decline among women (USDHHS, 1989) .
Lowering blood cholesterol among those at risk as a national public health effort is relatively new. Emerging trends already show that Ameri-Cans are increasingly aware that it is a risk factor for coronary heart disease, and are making changes to reduce the threat to their health. The percentage of adults who have ever had their blood cholesterol checked has risen from 35% in 1983 to 59% in 1988. The number of adults who know their blood cholesterol level has risen from 3% in 1983 to 17% in 1988-an almost sixfold increase , Levy, 1988 .
Today, more adults are concerned about their health and are willing to participate in efforts to enhance and It is incumbent on nurses to become familiar with pathophysiology of lipoproteins and the guidelines for their detection, treatment, and management.
maintain it. These efforts are particularly noticeable at the worksite, where 66% of American companies of over 50 employees are engaging in health promotion and disease prevention activities (USDHHS, 1987) . Occupational health nurses have the opportunity to enhance their efforts in worker health by including cholesterol reduction activities and programs in their health programs. As such, occupational health nurses must have the latest information concerning the identification, treatment, and management of elevated blood cholesterol in adults.
In 1988, the National Cholesterol Education Program (NCEP), coordinated by the National Heart, Lung, and Blood Institute, released The Report of the Mult Treatment Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Mults (NIH, 1989 ). This report is a set of guidelines formulated by a multidisciplinary panel of practicing clinicians, lipid experts, epidemiologists, nurses, behavioral scientists, and dietitians. The report is designed to provide guidance in the identification and treatment of adults 20 years and older who are at risk for CHD, based on their blood cholesterol levels.
The preparation of these guidelines is the result of decades of accumulated findings from basic research, animal studies, clinical trials, and prospective epidemiologic studies showing that a positive linear relationship exists between the level of blood cholesterol and the risk for CHD ( Figure) . Further evidence has also demonstrated that not only will lowering blood cholesterol decrease the risk for CHD, but it will retard atherosclerotic progression in persons with existing coronary disease (Blakenhorn, 1987 , Brown, 1989 , and in some cases results in plaque regression.
Based on the recommendations in the guidelines, as many as 60 million Americans will enter the health care system for the treatment of elevated blood cholesterol and many more for cholesterol screening (Sernpos, 1989) . Therefore, it is incumbent on nurses to become familiar with pathophysiology of lipoproteins and the guidelines for their detection, treatment, and management, and to implement such recommendations in their practice.
DETECTION AND CLASSIFICATION
The guidelines recommend that all adults 20 years of age and over have an initial cholesterol measurement. If dl and 240 mgldl correspond roughly to the 75th and 90th percentiles in the adult population. Compared with populations in many othe r indu strialized countries, Americans have among the highe st blood choleste rol levels and highest CHD rates. In earlier approaches to blood cholesterol detection and management, blood cholesterol levels that fell within the fifth to 95th percentiles of the United States population were considered "normal." This normal design ation has been shown to markedly und erestimate the importance of chole sterol as a risk factor, because popul ation stud ies have revealed that the major burden for CHD risk falls within the entire upper half of this range.
Although population risk cannot be applied to individuals as an absolute predictor of whe ther a particular disease will de velop, the new blood cholesterol risk cutpoints will increase the probability of identifying both individuals and the general population at risk for disease. Thus, intervention strategies can be designed and implemented to reduce CHD risk.
the total blood cholesterol is less than 200 mg/dl, considered a desirable level , re-measurement is recommended again within 5 years. Levels that fall within the range of 200 to 239 mg/dl are considered borderline high , and those that are 240 mgldl or above arc considered high (Table I) . For persons with confirmed levels of 240 mg/dl and for those in the borderline high range who also have two or more risk factors (Table 2) or known coronary disease, a further analysis of lipoproteins is recommended within 2 month s.
Because low density lipoprotein cholesterol (LDL) is the most atherogenic of the lipoprotein subfractions, it is the measurement that defines treatment decisions and goal levels. An LDL of less than 130 mg/dl is considered desirable, while levels of 130 to 159 mg/dl are considered borderline high risk, and levels of 160 mg/dl or greater are considered high risk.
The usual lipoprotein analysis, performed after a 12 to 14 hour fast, includes determin ations of total cholesterol (TC), triglycerides (TG), and high den sity lipoprotein s (H D L). From these measurements, the low density lipoprotein cholesterol (LDL) can be estimated using the Friedewald formula: LDL=TC -HDL -(TG/5). This formula is less accurate in persons whose triglyceride levels exceed 400 mg/dl and should not be used in these instances.
POPULATION VERSUS INDIVIDUAL RISK
Practitioners should note that these classification levels for cholesterol are based on population CHD risk curves, not on the population distribution of cholesterol. However, the total cholesterol cutpoints of 200 mg/
DIETARY AND DRUG TREATMENT
Person s whose total blood cholesterol levels fall within the 200 to 239 mgldl range and who have no other major risk factors should begin treatment with a Step One diet. This diet is de signed to reduce the intake of dietary choleste rol and total fat, particularly saturated fat. Treatment decisions for individuals who have other ' risk factors or clinical symptoms of coronary disease are based on LDL levels.
If persons have existing coron ary di sease o r two or more major risk factors, the goals for LDL levels are set at 130 mg/dl or lower. For those without existing disease or other risk factors , the go al s for LDL levels arc set at 160 mg/dl or lower. In all cases, dietary intervention sho uld be the keystone of treatment. If the Step One diet fails to achieve the blood cholesterol (NIH, 1989) Drug treatment is recommended after 6 months for those whose LDL levels fail to fall below 190 mg/dl with dietary intervention, or below 160 . . mg/dl for those with existing coronary disease or two major risk factors. Serial monitoring of total blood cholesterol levels every 6 to 12 weeks during treatment may be used to estimate the LDL response. Table 3 summarizes this treatment schema.
The guidelines provide specific information on the use of cholesterollowering drugs. Bile acid sequestrants and nicotinic acid are the preferred drugs because of their proven efficacy, success in reducing CHD risk, and long term safety. The new HMG Co-A reductase inhibitors, such as Lovastatin and others soon to follow, are effective in lowering blood cholesterol. However, they have not been used in clinical trials in which coronary disease is the outcome, and their long term safety has not been established.
Therefore, these and other medications would be recommended after an unsuccessful trial with the older, proven agents, or in combination therapy. Additional drugs such as probucol and gemfibrozil are recommended second line agents when combination therapy is required.
Where triglyceride levels are also elevated, gemfibrozil may be the preferred drug. Recent data from the Helsinki Heart Trial (Frick, 1987) indicate that gemfibrozil may have a greater potential for use as a first line drug because of its effects on lowering LDL and its ability to increase HDL substantially.
How to Obtain Additional Reference Material
To obtain a copy of an ideal posinon to identify risk factors for CHD early and to assist employees in changing their behaviors to reduce cardiovascular risk. Many occupational health nurses already have established smoking cessation and high blood pressure control programs in their companies.
Based on the accumulated scientific evidence on cholesterol, blood cholesterol identification and management programs can now be added to those and other CHD reduction and control efforts. Whether through specific cholesterol related activities or through a complete cholesterol education and treatment program, efforts to reduce blood cholesterol among employees at the workplace offer exciting opportunities, benefits, and challenges for employees, employers, and occupational health nurses.
A program of activities begins with an assessment of the problem. In blood cholesterol reduction efforts, part of the overall assessment includes screening---either on a limited basis for high risk individuals or a larger effort for the entire company population. Whatever level of effort is proposed, the recent introduction of the capillary fingerstick screening methods has made such assessments more manageable. The technology of fingerstick analysis has been shown to be reliable when conducted under controlled conditions by well trained personnel adhering to NHLBI public screening guidelines (Lundberg, 1988) . The technique is relatively painless, rapid, and convenient. It allows for immediate feedback to employees regarding their total blood cholesterol. Furthermore, the occupational health nurse can assess additional risk factors for CHD and initiate dietary education at the time of screening.
The occupational health nurse can decide, based on the results of the screening and other relevant assessments, where to initiate program efforts. The first step after screening is to refer workers with elevated blood cholesterol to their source of healthcare to have the screening value rechecked by repeating the test. This referral should be part of a carefully designed plan to provide periodic follow up reminders, thus allowing workers to receive the recheck and appropriate treatment.
A referral plan is important. Results from several cholesterol screening studies, including one clinical trial designed to improve referral completion with a follow up letter after screening, demonstrate that counseling alone at the time of screening results in low referral completion rates. These data suggest that screening without vigorous follow up will have little impact on the objective of screening-to get those at risk into treatment (Wynder, 1986; Rastam, 1988; Fitzgerald, Evaluation of Referral (USDHHS, 1989) .
One note of caution: individuals who fall within the desirable range at the time of screening should not be neglected. Take the time to review risk factors for CHD and explore ways of enhancing lifestyle patterns with these individuals. Remind those within the desirable range to have another blood cholesterol check in 5 years.
Another part of the referral effort is the relationship established with community healthcare providers. Many occupational health nurses are concerned about the different levels of awareness and understanding among community healthcare professionals regarding cholesterol identification and treatment. Some have experienced the dilemma of referring a worker with a moderate or high risk blood cholesterol screening level (~200 mg/dl) to community healthcare for a confirmation of the reading, only to have the worker return with the comment, "The doctor said 'Don't worry about ic."' A call to the physician from the occupational health nurse can often clarify the issue. If the worker's cholesterol level is indeed elevated, the occupational health nurse can serve as a liaison between the physician and the employee, explaining the rationale for early intervention. The occupational health nurse can also arrange to have materials such as The Report ofthe Adult Treatment Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults sent to the physician.
For the worker at moderate or high risk for CHD, the challenge of adhering to a treatment regimen requires daily lifestyle decisions which may not always be easy. This is an opportunity for the occupational health nurse to form an alliance with workers and their families tor health conservation and enhancement. These efforts can be enhanced further by support from supervisors and coworkers. Too often the social support networks of family, friends, and coworkers are overlooked; yet, they have been shown increasingly to be an important adjunct to therapy.
The decision to add cholesterol reduction efforts to existing programs or to initiate a new program in cholest-.erol education and reduction is an exciting challenge. Creating, maintaining, and evaluating program efforts may seem formidable tasks at first.
Help is often available through community organizations such as the American Heart Association, local hospitals, universities, and state health departments. All of these groups are active in cardiovascular disease risk factor reduction, and many have resources to assist 'worksites in establishing and maintaining programs. For example, consider the following possibilities. • Request program design and evaluation assistance from the health education department at a local college or university. • Seek assistance with screening from the local school of nursing. • Obtain the Heart at Work kit from the local American Heart Association. • Consult the local or state health department for resources. • Request materials from NHLBI (see box).
